Japan· JP-1179001M3022
アモキサピン
A amoxapine product containing アモキサピン, registered in Japan by ファイザー, on the national reimbursement list. The same ATC class is registered in 4 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Amoxapine is registered in 4 of 19 countries.
Countries holding a registration under ATC N06AA17 (amoxapine), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 2 of them publish a price we can compare per daily dose
Amoxapine · ATC N06AA17
4 / 19 countries
- Franceprice
- Japan
- United Kingdom
- United Statesprice
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- アモキサピン
- Manufacturer
- ファイザー
- Country
- Japan (JP)
- ATC code
- N06AA17
- ATC class
- Amoxapine
- Defined daily dose
- 0.15 g, O
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
305 interactions on record for amoxapine.
Graded by severity as the source publishes them — 65 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Amoxapine · interactions on record
305 records
- 65 severe
- 223 moderate
- 16 minor
Most severe, free to view
- PapaverineA03AD01severe
- MetoclopramideA03FA01severe
- CisaprideA03FA02severe
- OndansetronA04AA01severe
1 more interaction with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under N06AA17
Amoxapine, as other registers publish it.
- United StatesAmoxapineChartwell RX, LLC
- United StatesAmoxapineActavis Pharma, Inc.
- United StatesAmoxapineActavis Pharma, Inc.
- United StatesAmoxapineChartwell RX, LLC
- United StatesAmoxapineChartwell RX, LLC
- United StatesAmoxapineActavis Pharma, Inc.
- United StatesAmoxapineChartwell RX, LLC
- United StatesAmoxapineActavis Pharma, Inc.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/aabc431d-bf4b-4ccc-8052-2da4cdba654c GET /v1/drugs/aabc431d-bf4b-4ccc-8052-2da4cdba654c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "５０ｍｇ１カプセル",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "1179001M3022",
"category": "内用薬",
"price_yen": 11.1,
"generic_name": "アモキサピン",
"product_name_jp": null,
"therapeutic_class": "1179",
"transitional_expiry": "R9.3.31まで"
}See everything about amoxapine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.